Shilpa Gupta, Director of Genitourinary Oncology at the Cleveland Clinic, shared a post on X by Andrea Necchi, Associate Editor at Journal of Clinical Oncology, adding:
“Congrats Andrea Necchi, Sia Daneshmand, Michiel van der Heijden entire SunRISe-1 team on this BIG step forward for patients with BCG-unresponsive NMIBC!”
Quoting Andrea Necchi‘s post:
“Important news for our patients following the Journal of Clinical Oncology publication of SunRIse1 primary results.”
Title: TAR-200 for Bacillus Calmette-Gu ´ erin–Unresponsive. High-Risk Non–Muscle-Invasive Bladder Cancer: Results. From the Phase IIb SunRISe-1 Study
Authors: Siamak Daneshmand, Michiel S. Van der Heijden, Joseph M. Jacob, Felix Guerrero-Ramos, Martin Bogemann, Giuseppe Simone, Christopher M. Pieczonka, Nelson Canales Casco, Daniel Zainfeld, Philipp Spiegelhalder, Evanguelos Xylinas, David Cahn, Yair Lotan, Katie S. Murray, Takashi Kawahara, Katharine Stromberg, Jason Martin, Abhijit Shukla, Christopher J. Cutie, Kristi Bertzos, Shalaka Hampras, Hussein Sweiti, Andrea Necchi
Read the Full Article in ASCO pubs.
Earlier Ashish M. Kamat, Endowed Professor and Surgeon at MD Anderson Cancer Center, shared a post about a recent FDA approval, adding:
“On September 9, 2025, the Food and Drug Administration approved gemcitabine intravesical system (Inlexzo, Janssen Biotech, Inc.) for adults with BCG – unresponsive NMIBC with CIS with or without papillary tumors.
Also known as TAR-200: this gemcitabine intravesical system is co-packaged with a urinary catheter and stylet used for insertion through the urinary catheter into the bladder.”
More posts featuring Andrea Necchi on OncoDaily.